DK1497440T3 - Stabile adenovirale vektorer og fremgangsmåder til propagering deraf - Google Patents
Stabile adenovirale vektorer og fremgangsmåder til propagering derafInfo
- Publication number
- DK1497440T3 DK1497440T3 DK03753569T DK03753569T DK1497440T3 DK 1497440 T3 DK1497440 T3 DK 1497440T3 DK 03753569 T DK03753569 T DK 03753569T DK 03753569 T DK03753569 T DK 03753569T DK 1497440 T3 DK1497440 T3 DK 1497440T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- propagation
- complementing cell
- pix
- adenoviral vectors
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000013598 vector Substances 0.000 title abstract 3
- 241000701161 unidentified adenovirus Species 0.000 abstract 3
- 238000004806 packaging method and process Methods 0.000 abstract 2
- 101150029662 E1 gene Proteins 0.000 abstract 1
- 101710114676 E1B 55 kDa protein Proteins 0.000 abstract 1
- 108700026244 Open Reading Frames Proteins 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Steroid Compounds (AREA)
- Lubricants (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL0200281 | 2002-04-25 | ||
| NL0200656 | 2002-10-15 | ||
| EP02102631 | 2002-11-25 | ||
| PCT/EP2003/050126 WO2004001032A2 (en) | 2002-04-25 | 2003-04-24 | Stable adenoviral vectors and methods for propagation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1497440T3 true DK1497440T3 (da) | 2008-12-01 |
Family
ID=34068720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03753569T DK1497440T3 (da) | 2002-04-25 | 2003-04-24 | Stabile adenovirale vektorer og fremgangsmåder til propagering deraf |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7285265B2 (da) |
| EP (1) | EP1497440B1 (da) |
| JP (1) | JP4495588B2 (da) |
| KR (1) | KR101006594B1 (da) |
| CN (1) | CN100374574C (da) |
| AT (1) | ATE405663T1 (da) |
| AU (1) | AU2003271738C1 (da) |
| CA (1) | CA2478508C (da) |
| DE (1) | DE60323080D1 (da) |
| DK (1) | DK1497440T3 (da) |
| ES (1) | ES2310247T3 (da) |
| IL (1) | IL164802A0 (da) |
| NO (1) | NO334299B1 (da) |
| NZ (1) | NZ534865A (da) |
| PL (1) | PL208588B1 (da) |
| SI (1) | SI1497440T1 (da) |
| WO (1) | WO2004001032A2 (da) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE445705T1 (de) | 1995-06-15 | 2009-10-15 | Crucell Holland Bv | Verpackungssysteme für humane rekombinante adenoviren zur gentherapie |
| US6929946B1 (en) * | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
| US20050232900A1 (en) * | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6913922B1 (en) * | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| PT1497438E (pt) * | 2002-04-25 | 2010-02-04 | Crucell Holland Bv | Meios e métodos para a produção de vectores de adenovírus |
| US20060099178A1 (en) | 2002-05-27 | 2006-05-11 | Holm Per S | Novel use of adenoviruses and nucleic acids coding therefor |
| CA2495546A1 (en) * | 2002-08-22 | 2004-03-04 | Merck & Co., Inc. | Methods for propagating adenovirus and virus produced thereby |
| WO2005010149A2 (en) * | 2003-07-18 | 2005-02-03 | Onyx Pharmaceuticals, Inc. | Subgroup b adenoviral vectors for treating disease |
| JP2007511211A (ja) | 2003-11-14 | 2007-05-10 | ホルム，ペル・ゾンネ | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
| CN1922308A (zh) | 2004-02-23 | 2007-02-28 | 克鲁塞尔荷兰公司 | 病毒纯化方法 |
| EA012037B1 (ru) | 2004-11-16 | 2009-06-30 | Круселл Холланд Б.В. | Поливалентные вакцины, содержащие рекомбинантные вирусные векторы |
| EP1831382B1 (en) | 2004-12-31 | 2023-01-18 | Per Sonne Holm | Method for reversing multiple resistance in animal cells |
| US20090232800A1 (en) * | 2004-12-31 | 2009-09-17 | Per Sonne Holm | E1-minus adenoviruses and use thereof |
| CA2602944C (en) | 2005-04-11 | 2015-08-11 | Crucell Holland B.V. | Virus purification using ultrafiltration |
| CN101248186A (zh) * | 2005-05-23 | 2008-08-20 | 瓦克辛公司 | 不含腺病毒的重组腺病毒载体的快速生产 |
| EP1998804B1 (en) * | 2006-03-27 | 2014-04-16 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
| CN101631454A (zh) | 2006-12-08 | 2010-01-20 | 衣阿华州立大学研究基金公司 | 参与硝酸盐吸收和代谢的植物基因 |
| WO2010060719A1 (en) | 2008-11-03 | 2010-06-03 | Crucell Holland B.V. | Method for the production of adenoviral vectors |
| HRP20181776T1 (hr) | 2008-11-18 | 2019-02-08 | Beth Israel Deaconess Medical Center, Inc. | Antivirusna cjepiva sa poboljšanom staničnom imunogenosti |
| KR20120052352A (ko) | 2009-08-07 | 2012-05-23 | 트랜스진 에스.에이. | Ｈｂｖ 감염을 치료하는 조성물 |
| EP2618838A1 (en) | 2010-09-20 | 2013-07-31 | Crucell Holland B.V. | Therapeutic vaccination against active tuberculosis |
| US9168292B2 (en) | 2010-09-27 | 2015-10-27 | Crucell Holland B.V. | Heterologous prime boost vaccination regimen against malaria |
| WO2012082918A1 (en) | 2010-12-14 | 2012-06-21 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Adenovirus serotype 26 and serotype 35 filovirus vaccines |
| MY170927A (en) | 2011-11-28 | 2019-09-19 | Janssen Vaccines & Prevention Bv | Influenza virus vaccines and uses thereof |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| CA2864956C (en) | 2012-03-12 | 2021-11-09 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
| AP2014007993A0 (en) | 2012-03-22 | 2014-10-31 | Crucell Holland Bv | Vaccine against RSV |
| US10240128B2 (en) * | 2012-07-04 | 2019-03-26 | Sirion Biotech Gmbh | Means and methods to increase adenovirus production |
| WO2014078688A2 (en) * | 2012-11-16 | 2014-05-22 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and use thereof |
| CN110590916A (zh) | 2013-04-25 | 2019-12-20 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| BR112017003891A2 (pt) | 2014-09-03 | 2017-12-26 | Bavarian Nordic As | métodos e composições para induzir imunidade protetora contra infecção por filovírus |
| KR20190062617A (ko) | 2014-09-03 | 2019-06-05 | 버베리안 노딕 에이/에스 | 면역 반응을 증대시키기 위한 방법 및 조성물 |
| PT3197489T (pt) | 2014-09-26 | 2021-04-30 | Beth Israel Deaconess Medical Ct Inc | Métodos e composições para induzir a imunidade protetora contra a infeção pelo vírus da imunodeficiência humana |
| TWI710635B (zh) * | 2014-10-09 | 2020-11-21 | 美商珍維克公司 | 編碼人類無調同源物-1(hath1)之腺病毒載體 |
| SI3283634T1 (sl) | 2015-04-14 | 2019-08-30 | Janssen Vaccines & Prevention B.V. | Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem |
| BE1023877B1 (fr) | 2015-05-21 | 2017-09-01 | Glaxosmithkline Biologicals Sa | Procédés et compositions pour l’induction d’une immunité protectrice contre une maladie et/ou une infection à filovirus |
| US10457708B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
| JP7189014B2 (ja) | 2015-07-07 | 2022-12-13 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Ｒｓｖに対するワクチン |
| CN108368157B (zh) | 2015-12-15 | 2022-04-15 | 扬森疫苗与预防公司 | 人类免疫缺陷病毒抗原、载体、组合物、及其使用方法 |
| KR20220041966A (ko) | 2016-04-05 | 2022-04-01 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 용해성 융합-전 rsv f 단백질 |
| BR112018070323A2 (pt) | 2016-04-05 | 2019-01-29 | Janssen Vaccines & Prevention Bv | vacina contra rsv |
| WO2017194655A1 (en) | 2016-05-12 | 2017-11-16 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
| IL264119B2 (en) | 2016-05-30 | 2023-04-01 | Janssen Vaccines Prevention B V | f proteins of rsv are stabilized before fusion |
| MX392862B (es) | 2016-06-16 | 2025-03-24 | Janssen Vaccines & Prevention Bv | Formulación de vacuna contra el vih. |
| EP3472327B1 (en) | 2016-06-20 | 2020-08-19 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
| EP3484506A1 (en) | 2016-07-14 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Hpv vaccines |
| US10925955B2 (en) | 2016-07-15 | 2021-02-23 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a Marburg virus infection |
| EP3484507A1 (en) | 2016-07-15 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
| EP3526236B1 (en) | 2016-10-17 | 2025-12-10 | Beth Israel Deaconess Medical Center, Inc. | Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same |
| CN110268061B (zh) | 2017-02-09 | 2024-07-16 | 扬森疫苗与预防公司 | 用于表达异源基因的有效的短启动子 |
| WO2018185732A1 (en) | 2017-04-06 | 2018-10-11 | Janssen Vaccines & Prevention B.V. | Mva-bn and ad26.zebov or ad26.filo prime-boost regimen |
| MX2019013259A (es) | 2017-05-08 | 2020-01-13 | Gritstone Oncology Inc | Vectores de neoantigeno de alfavirus. |
| WO2018210871A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| AU2018267971A1 (en) | 2017-05-17 | 2019-11-07 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
| WO2018229711A1 (en) | 2017-06-15 | 2018-12-20 | Janssen Vaccines & Prevention B.V. | Poxvirus vectors encoding hiv antigens, and methods of use thereof |
| AU2018306614B2 (en) | 2017-07-28 | 2024-08-29 | Janssen Vaccines & Prevention B.V. | Methods and compositions for heterologous repRNA immunizations |
| SG11202001458SA (en) | 2017-09-15 | 2020-03-30 | Janssen Vaccines & Prevention Bv | Method for the safe induction of immunity against rsv |
| BR112020007884A2 (pt) | 2017-11-20 | 2020-11-03 | Janssen Pharmaceuticals, Inc. | método de proporcionar uma administração segura de vetores adenovirais que codificam um antígeno de vírus zika |
| EP3723771A4 (en) | 2017-12-11 | 2022-04-06 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and uses thereof |
| MX2020006471A (es) | 2017-12-19 | 2020-09-22 | Janssen Sciences Ireland Unlimited Co | Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv). |
| EP4495597A3 (en) | 2018-01-04 | 2025-04-30 | Iconic Therapeutics LLC | Anti-tissue factor antibodies, antibody-drug conjugates, and related methods |
| BR112021000274A2 (pt) | 2018-07-20 | 2021-04-06 | Janssen Vaccines & Prevention B.V. | Vetor adenoviral recombinante expressando antígeno de zika com produtividade melhorada |
| JOP20210106A1 (ar) | 2018-11-13 | 2023-01-30 | Janssen Vaccines And Prevention B V | بروتينات rsv f سابقة الاندماج مستقرة |
| KR20220008816A (ko) | 2019-05-15 | 2022-01-21 | 얀센 백신스 앤드 프리벤션 비.브이. | 아데노바이러스 기반 백신을 사용한 호흡기 세포융합 바이러스 감염의 예방적 치료 |
| BR112021022087A2 (pt) | 2019-05-15 | 2021-12-28 | Janssen Vaccines & Prevention Bv | Coadministração de vacina sazonal contra influenza e vacina contra vírus respiratório sincicial à base de adenovírus |
| JP7457733B2 (ja) | 2019-05-30 | 2024-03-28 | グリットストーン バイオ インコーポレイテッド | 改変アデノウイルス |
| CN110714027A (zh) * | 2019-10-28 | 2020-01-21 | 嘉铭(固安)生物科技有限公司 | 一种表达质粒、用于包装二代腺病毒的细胞株及其应用 |
| IL299571A (en) | 2020-07-08 | 2023-02-01 | Janssen Sciences Ireland Unlimited Co | Rna replicon vaccines against hbv |
| EP4192496A4 (en) | 2020-08-06 | 2025-01-01 | Gritstone bio, Inc. | MULTIEPITOP VACCINE CASSETTES |
| WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
| CN117821405B (zh) * | 2023-11-24 | 2024-11-26 | 广州医科大学 | 基因嵌合型人腺病毒及其构建方法和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| IL116816A (en) * | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
| ATE445705T1 (de) * | 1995-06-15 | 2009-10-15 | Crucell Holland Bv | Verpackungssysteme für humane rekombinante adenoviren zur gentherapie |
| US5922315A (en) | 1997-01-24 | 1999-07-13 | Genetic Therapy, Inc. | Adenoviruses having altered hexon proteins |
| JP2002513290A (ja) | 1997-05-08 | 2002-05-08 | ジェネティック・セラピー・インコーポレテッド | 修飾されたファイバー蛋白質を有するアデノウイルスによる遺伝子移入 |
| US6670188B1 (en) | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| DE60039683D1 (de) | 1999-03-04 | 2008-09-11 | Crucell Holland Bv | Verwendung eines adenovirusvektors zur transduktion von synovialen zellen |
| DK1818408T3 (da) * | 1999-05-17 | 2011-10-17 | Crucell Holland Bv | Rekombinant adenovirus af serotypen Ad11 |
| US6492169B1 (en) * | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US6365394B1 (en) * | 1999-09-29 | 2002-04-02 | The Trustees Of The University Of Pennsylvania | Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus |
| EP1103610A1 (en) | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
| DE10045687B4 (de) * | 2000-09-15 | 2006-07-06 | MICROMUN Privates Institut für Mikrobiologische Forschung GmbH Biotechnikum Greifswald | Expressionskassetten und Adenovirusvektoren |
| WO2002024730A2 (en) | 2000-09-20 | 2002-03-28 | Crucell Holland B.V. | Transduction of dendritic cells using adenoviral vectors |
| WO2002053759A1 (en) | 2001-01-04 | 2002-07-11 | Wadell Goeran | Viral vector for gene therapy |
| PT1497438E (pt) | 2002-04-25 | 2010-02-04 | Crucell Holland Bv | Meios e métodos para a produção de vectores de adenovírus |
-
2003
- 2003-04-24 DK DK03753569T patent/DK1497440T3/da active
- 2003-04-24 NZ NZ534865A patent/NZ534865A/en not_active IP Right Cessation
- 2003-04-24 CN CNB038092085A patent/CN100374574C/zh not_active Expired - Fee Related
- 2003-04-24 IL IL16480203A patent/IL164802A0/xx active IP Right Grant
- 2003-04-24 WO PCT/EP2003/050126 patent/WO2004001032A2/en not_active Ceased
- 2003-04-24 JP JP2004514868A patent/JP4495588B2/ja not_active Expired - Lifetime
- 2003-04-24 ES ES03753569T patent/ES2310247T3/es not_active Expired - Lifetime
- 2003-04-24 AU AU2003271738A patent/AU2003271738C1/en not_active Ceased
- 2003-04-24 PL PL373337A patent/PL208588B1/pl unknown
- 2003-04-24 KR KR1020047016964A patent/KR101006594B1/ko not_active Expired - Fee Related
- 2003-04-24 DE DE60323080T patent/DE60323080D1/de not_active Expired - Lifetime
- 2003-04-24 US US10/512,602 patent/US7285265B2/en not_active Expired - Lifetime
- 2003-04-24 SI SI200331429T patent/SI1497440T1/sl unknown
- 2003-04-24 CA CA2478508A patent/CA2478508C/en not_active Expired - Fee Related
- 2003-04-24 AT AT03753569T patent/ATE405663T1/de active
- 2003-04-24 EP EP03753569A patent/EP1497440B1/en not_active Expired - Lifetime
-
2004
- 2004-11-24 NO NO20045131A patent/NO334299B1/no not_active IP Right Cessation
-
2007
- 2007-09-05 US US11/899,572 patent/US8052967B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8052967B2 (en) | 2011-11-08 |
| CN100374574C (zh) | 2008-03-12 |
| WO2004001032A2 (en) | 2003-12-31 |
| JP2005523730A (ja) | 2005-08-11 |
| US20080206837A1 (en) | 2008-08-28 |
| KR101006594B1 (ko) | 2011-01-07 |
| NZ534865A (en) | 2008-07-31 |
| AU2003271738B2 (en) | 2007-10-11 |
| US7285265B2 (en) | 2007-10-23 |
| CA2478508A1 (en) | 2003-12-31 |
| NO334299B1 (no) | 2014-02-03 |
| CN1650021A (zh) | 2005-08-03 |
| EP1497440B1 (en) | 2008-08-20 |
| JP4495588B2 (ja) | 2010-07-07 |
| CA2478508C (en) | 2013-07-02 |
| EP1497440A2 (en) | 2005-01-19 |
| ES2310247T3 (es) | 2009-01-01 |
| ATE405663T1 (de) | 2008-09-15 |
| KR20040106365A (ko) | 2004-12-17 |
| AU2003271738C1 (en) | 2008-04-17 |
| PL208588B1 (pl) | 2011-05-31 |
| HK1069185A1 (en) | 2005-05-13 |
| NO20045131L (no) | 2005-01-21 |
| US20050163753A1 (en) | 2005-07-28 |
| SI1497440T1 (sl) | 2009-02-28 |
| DE60323080D1 (de) | 2008-10-02 |
| PL373337A1 (en) | 2005-08-22 |
| AU2003271738A1 (en) | 2004-01-06 |
| IL164802A0 (en) | 2005-12-18 |
| WO2004001032A3 (en) | 2004-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1497440T3 (da) | Stabile adenovirale vektorer og fremgangsmåder til propagering deraf | |
| DK1497438T3 (da) | Midler og fremgangsmåder til fremstilling af adenovirusvektorer | |
| Imler et al. | Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors. | |
| ES2151310T3 (es) | Nuevas lineas celulares de complementacion para vectores adenovirales defectivos. | |
| IS4754A (is) | Genaferjur og aðferðir fyrir genaflutning inn í frumur | |
| WO2006065827A3 (en) | Cell lines for production of replication-defective adenovirus | |
| DK2402450T3 (da) | Fremgangsmåder til opnåelse af rekombinante proteiner med reducerede LacdiNac-strukturer | |
| NO20004563D0 (no) | Modifisert adenovirus som inneholder et fibererstatningsprotein | |
| DK1226264T3 (da) | Cellelinjer og konstruktioner, der er nyttige i fremstillingen af E1-deleterede adenovirus i fravær af replikationskompetent adenovirus | |
| WO2004099422A3 (en) | Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes | |
| ATE246252T1 (de) | Von adenovirus abgeleitete rekombinante vektoren, für gentherapie | |
| WO2006127956A3 (en) | Rapid production of adenovirus-free recombinant adenovirus vectors | |
| WO2004018627A3 (en) | Methods for propagating adenovirus and virus produced thereby | |
| CA2538025A1 (en) | Packaging cells for recombinant adenovirus | |
| WO2004015086A3 (en) | Enhancement of adenoviral oncolytic activity in prostate cells by modification of the e1a gene product | |
| SI1760153T1 (sl) | Adenovirusni/alfavirusni hibridni vektor za uäśinkovito uporabo in ekspresijo terapevtskih genov v tumorskih celicah | |
| WO2006060089A3 (en) | Novel methods for producing adenoviral vector preparations with reduced replication-competent adenovirus contamination and novel adenoviral vectors and preparations | |
| Löser et al. | Construction, rescue, and characterization of vectors derived from ovine atadenovirus | |
| WO2004033696A3 (fr) | Vecteurs adenoviraux recombinants et leurs applications | |
| IL116216A0 (en) | Encapsidation cell lines and expression vectors for the transcomplementation of defective retroviral vector | |
| Schiedner et al. | Human cell lines for production of biopharmaceuticals | |
| TW200607859A (en) | Oncolytic adenoviral vectors encoding GM-CSF | |
| Oda et al. | Isolation of Golgi fractions from colchicine-treated rat liver. II. Electrophoretic characterization. | |
| WO2003074692A3 (de) | Spezifische genexpression in kolonkarzinom-zell-linien | |
| 長尾雅悅 | źj; F f H C. 43 (E535-Tryptophan 2, 3-dioxygenase 3% H3 DH% |